

1 **Testing the association between tobacco and cannabis use and cognitive functioning:**

2 **Findings from an observational and Mendelian randomization study**

3

4 Liam Mahedy^{1,2,3} (Ph.D.), Robyn Wootton^{1,2,3} (Ph.D.), Steph Suddell^{1,2,3} (MSc), Caroline

5 Skirrow^{1,4}, (Ph.D.), Matt Field⁵ (Ph.D.), Jon Heron⁶ (Ph.D.), Matthew Hickman⁶ (Ph.D.),

6 Marcus R. Munafò^{1,2,3} (Ph.D.)

7

8 **Affiliations**

9 ¹School of Psychological Science, University of Bristol, Bristol, UK.

10 ²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

11 ³National Institute for Health Research Biomedical Research Centre at the University

12 Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK.

13 ⁴Cambridge Cognition, Cambridge, UK.

14 ⁵Department of Psychology, University of Sheffield, Sheffield, UK.

15 ⁶Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

16

17 **Corresponding author:** Liam Mahedy, School of Psychological Science, University of Bristol,

18 12a Priory Road, Bristol, UK, BS8 1TU.

19 Tel: +44 (0) 117 33 10616; Email: liam.mahedy@bristol.ac.uk

20

21 **Key words:** ALSPAC, cannabis, tobacco, cognition, longitudinal latent class analysis,

22 Mendelian randomization.

23

24 **Word count:** 4,032 (excluding Abstract, Figures, Tables and References) used to guide clinical practice.

25 **Abstract**

26 **Background:** Although studies have examined the association between tobacco and
27 cannabis use in adolescence with subsequent cognitive functioning, study designs are
28 usually not able to distinguish correlation from causation.

29 **Methods:** First, separate patterns of tobacco and cannabis use were derived using
30 longitudinal latent class analysis based on measures assessed on five occasions from ages 13
31 to 18 years in a large UK based population cohort (ALSPAC). Cognitive functioning measures
32 comprised working memory, response inhibition, and emotion recognition assessed at 24
33 years of age. One- and two-sample Mendelian randomization, methods for testing causal
34 inference using genetic variants as proxies for an exposure of interest, were used to
35 examine the causal relationship between smoking initiation/lifetime cannabis use, and
36 subsequent cognitive functioning in ALSPAC.

37 **Results:** We found evidence of a relationship between tobacco and cannabis use and
38 diminished cognitive functioning for each of the outcomes in the observational analyses.
39 The clearest evidence demonstrated a dose-response relationship between tobacco use and
40 working memory suggesting late-onset regular tobacco smokers ($b=-0.29$, 95%CI=-0.45 to -
41 0.13), early-onset regular smokers ($b=-0.45$, 95%CI=-0.84 to -0.05), and early-onset regular
42 cannabis users ($b=-0.62$, 95%CI=-0.93 to -0.31) performed worse on this task compared to
43 individuals with a very low probability of using tobacco/cannabis. Mendelian randomization
44 analyses were imprecise and did not provide additional support for these results.

45 **Conclusions:** Overall, there was some evidence to suggest that adolescent tobacco and
46 cannabis use were associated with diminished cognitive functioning. Better powered
47 genetic studies are required to determine whether these associations are causal.

48

49 INTRODUCTION

50 Tobacco and cannabis use during adolescence, when the brain is still developing and
51 undergoing considerable structural and function changes (1), is a major public health
52 concern. The association between adolescent tobacco and cannabis use and subsequent
53 cognitive functioning has received particular attention because certain cognitive functions
54 (e.g. working memory, response inhibition, and emotion recognition) do not peak until early
55 adulthood (2–5) in parallel with maturation of the prefrontal cortex (6,7). Due to the
56 prolonged neurodevelopmental period and the potential for the endocannabinoid and
57 nicotinic cholinergic signalling systems to be involved in altering development (8,9), it is
58 plausible that tobacco and cannabis use during this potentially critical period could play a
59 role in disrupting normal brain development (10–13). Nonetheless, there is still uncertainty
60 regarding the nature of the association between tobacco and cannabis use and
61 neurocognitive function.

62 A recent review of prospective studies of the association between cannabis use and
63 cognition in young people (14) highlighted an association between cannabis use and
64 neuropsychological decline (15,16). However, these studies often fail to control for
65 neurocognitive measures prior to cannabis use (17,18) and associations were largely found
66 for the heaviest cannabis users and were often attenuated when potential confounders (e.g.
67 other forms of substance use) were included (16,19). A recent study (20), using a co-twin
68 design (allowing for the disentanglement of shared environmental and genetic factors),
69 assessed IQ prior to cannabis initiation and found insufficient evidence to suggest cannabis
70 use was associated with decline in general IQ. Findings from two recent longitudinal studies
71 of adolescents (21,22) using a repeated measures design suggest that the association
72 between cognitive functioning and cannabis use could be bidirectional.

73 The direction of association between tobacco and cognitive functioning is also
74 unclear as there is a lack of epidemiological studies that have prospectively examined this
75 relationship. Evidence from animal studies suggests that nicotine exposure may have more
76 deleterious developmental effects during adolescence, when the brain is thought to be
77 more vulnerable (23). Furthermore, human studies suggest that nicotine has a more potent
78 effect when consumed in late adolescence compared to in adulthood (24). One small
79 prospective study ($n=112$, aged between 17 to 21 years) found that current smokers
80 performed worse than non-smokers on a variety of cognitive assessments including
81 language related IQ and working memory while controlling for earlier cognitive measures
82 and other substance use (25). Finally, one large study ($n\sim 20,000$) on Israeli male soldiers
83 (26) found a dose-response relationship between number of cigarettes smoked and lower
84 general cognitive ability compared to non-smokers. They also found diminished cognitive
85 functioning in individuals who started starting smoking after 18 years of age.

86 In an effort to strengthen the evidence, we used data from the Avon Longitudinal
87 Study of Parents and Children, a large UK prospective birth cohort, to investigate whether
88 patterns of adolescent tobacco and cannabis use were prospectively associated with
89 cognitive functioning at 24 years of age. As young people do not initiate tobacco or cannabis
90 at the same time (27,28), we used longitudinal latent class analysis (LLCA) to identify
91 heterogenous classes of individuals with different tobacco and cannabis use profiles across
92 adolescence (29). As a next step we used genetic variants that are separately associated
93 with smoking initiation and lifetime cannabis use to perform one- and two-sample
94 Mendelian randomization (MR) to improve causal inference (30). We expected to find that
95 an earlier age of onset and more frequent use (for both substances) would be associated
96 with larger reductions in cognitive function, and that the MR analyses would demonstrate

97 the hypothesised associations between tobacco and cannabis use and diminished cognitive
98 functioning.

99

100 **METHODS**

101 **Observational analyses**

102 *Participants and Procedure*

103 The Avon Longitudinal Study of Parents and Children (ALSPAC) is a cohort born in 1991–92.
104 ALSPAC recruited 14,541 pregnant women resident in Avon, UK, with expected dates of
105 delivery between 1 April 1991 and 31 December 1992. The initial number of pregnancies
106 enrolled is 14,541 (for these at least one questionnaire has been returned or a “Children in
107 Focus” clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total
108 of 14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at 1
109 year of age. When the oldest children were approximately 7 years of age, an attempt was
110 made to bolster the initial sample with eligible cases who had failed to join the study
111 originally. The total sample size for analyses using any data collected after the age of 7 years
112 is therefore 15,454 pregnancies, resulting in 15,589 fetuses. Of this total sample 14,901
113 were alive at 1 year of age (31–33). Of these, 9,997 offspring were invited to attend the 24-
114 year clinic assessment. A detailed overview of our study population, including attrition at
115 the different measurement occasions is presented in Supplementary Material Figure S1.
116 Detailed information about ALSPAC is available online www.bris.ac.uk/alspac. A fully
117 searchable data dictionary is available on the study’s website
118 <http://www.bristol.ac.uk/alspac/researchers/our-data/>. Approval for the study was
119 obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics
120 Committees. Informed consent for the use of data collected via questionnaires and clinics

121 was obtained from participants following recommendations of the ALSPAC Ethics and Law
122 Committee at the time. Consent for biological samples was collected in accordance with the
123 Human Tissue Act (2004).

124 **Measures**

125 A timeline of data collection is presented in Supplementary Material Figure S2.

126 *Exposure variables*

127 Information on tobacco and cannabis use were collected on six occasions via
128 questionnaire (Q) or during attendance at a study clinic (C). Median ages at response were:
129 13y(C), 14y(Q), 15y(C) 16y(Q), 17y(C), and 18y(Q).

130 *Tobacco use*

131 Patterns of tobacco use have been described in detail elsewhere (34). Responses to
132 one or more questions at each time point were used to derive a repeated four-level ordinal
133 variable with categories 'Non-smoker', 'Occasional smoker' (typically less than once per
134 week), 'Weekly smoker' and 'Daily smoker'. There was good agreement that a four-class
135 solution was adequate in explaining the heterogeneity in tobacco based on model fit criteria
136 (see Table S1a). The four-class model ($n=8,525$) comprised individuals with a higher
137 probability of 'early-onset regular smokers' (3.4%), 'late-onset regular smokers' (11.6%),
138 'experimenters' (17.4%), and 'non-smokers' (67.5%) (Figure 1a).

139 *Cannabis use*

140 Patterns of cannabis use have been described in detail elsewhere (35). Responses to
141 one or more questions at each time point were used to derive a repeated three-level ordinal
142 variable with categories 'Do not use', 'Occasional use' (typically less than once per week)
143 and 'Frequent use' (typically once per week or more). There was good agreement that a
144 four-class solution was adequate in explaining the heterogeneity in cannabis use based on

145 model fit criteria (see Table S1b). The four-class model ($n=8,093$) comprised individuals with
146 a higher probability of ‘early-onset regular users’ (3.6%), ‘early-onset occasional users’
147 (2.9%), ‘late-onset occasional users’ (13.8%), and ‘non-users’ (79.8%) (Figure 1b).

148 *Outcome variables*

149 At 24 years of age ($M=24.0$ years; $SD=9.8$ months) participants attended a clinic-
150 based assessment which included computerised cognitive assessments as part of a broader
151 assessment battery of mental and physical health and behaviour. Data collection for the
152 online questionnaires was collected and managed by REDcap electronic data capture tools
153 (36,37). Further information on all three cognitive tasks is presented in Supplementary
154 material.

155 *Working memory*

156 The N -back task (2-back condition) was used to assess working memory. The N -back
157 task (38) is widely used to measure working memory (39–41). A measure of discriminability
158 (d') was chosen as the primary outcome measure given it is an overall performance
159 estimate. High scores on *number of hits* indicated more accurate identification, while high
160 scores on *false alarms* indicated less accurate identification. High scores on d' , therefore,
161 indicated a greater ability to distinguish signal from noise. d' data were available for $n=3,242$
162 participants.

163 *Response inhibition*

164 The Stop Signal Task (42) was used to assess response inhibition – the ability to
165 prevent an ongoing motor response. The task consisted of 256 trials, which included a 4:1
166 ratio of trials without stop signals to trials with stop signals. Mean response times were
167 calculated. An estimate of *stop signal reaction time* (SSRT) was calculated using the median
168 of the inhibition function approach (43). SSRT used as the primary outcome as it is a reliable

169 measure of inhibitory control, with shorter reaction times indicating faster inhibition. SSRT
170 data were available for 3,201 participants.

171 *Emotion recognition*

172 Emotion recognition was assessed using a six alternative forced choice (6AFC)
173 emotion recognition task (44) comprising of 96 trials (16 for each emotion) which measures
174 the ability to identify emotions in facial expressions that vary in intensity. In each trial,
175 participants were presented with a face displaying one of six emotions: anger, disgust, fear,
176 happiness, sadness, or surprise. Participants were required to select the descriptor that best
177 described the emotion that was present in the face, using the computer mouse. Emotion
178 intensity varied across 8 levels within each emotion from the prototypical emotion to an
179 almost neutral face. Each individual stimulus was presented twice, giving a total of 96 trials.
180 An overall measure of ER (the number of facial emotions accurately identified) was used as
181 the primary outcome. ER data were available for $n=3,368$ participants.

182 *Potential confounders*

183 Confounders comprised of established risk factors for cognitive functioning that
184 could plausibly have a relationship with earlier substance use. Potential confounders
185 included: income, maternal education, socioeconomic position, housing tenure, sex, and
186 maternal smoking during first trimester in pregnancy. Working memory at approximately 11
187 years and experience of a head injury/unconsciousness up to 11 years were included to
188 control for cognitive functioning prior to baseline measures of substance use. The inclusion
189 of both measures helps to control for the possibility that the onset of substance use is
190 caused by impaired or lower cognitive performance, thereby allowing for the temporal
191 order between substance use and later cognitive functioning to be established. Finally, a
192 measure of alcohol use asking whether they had ever had a whole drink of alcohol was

193 collected at age 13 years (up to the first assessment of smoking and cannabis use). Further
194 information is presented in Supplementary material.

195 *Statistical methods*

196 Different tobacco and cannabis phenotypes were used across different analytic
197 methods.

198 *Observational analyses*

199 Tobacco and cannabis class membership was related to covariates using the Bolck-
200 Croon-Hagenaars (45) method. This approach uses the weights derived from the latent
201 classes to reflect measurement error in the latent class variable. Linear regression was used
202 to examine the association between the cognitive outcomes and latent class membership
203 controlling for the confounding variables. Results are reported as unstandardized beta
204 coefficients with 95% confidence intervals. Analyses were carried out using Mplus 8.4 (46).

205 *Missing data*

206 Missing data was dealt with in three steps. First, full information maximum
207 likelihood (FIML) was used to derive trajectories tobacco (N=8,525) and cannabis (N=8,093)
208 based on individuals who had information on at least one timepoint between 13 and 18
209 years. For a detailed description of missingness at each timepoint see Tables S2a and S2b.
210 Next, multiple imputation was based on 3,232 participants (for both tobacco and cannabis
211 models) who had information on at least one of the cognitive outcomes. The imputation
212 model (based on 100 datasets) contained performance on all of the cognitive tasks, all
213 measures of tobacco and cannabis use, and potential confounding variables, as well as a
214 number of auxiliary variables known to be related to missingness (e.g., substance use in
215 early adolescence, parental financial difficulties, and other SES variables). Finally, inverse
216 probability weighting was used where estimates of prevalence and associations were

217 weighted to account for probabilities of non-response to attending the clinic. See Table S3
218 for a detailed description of attrition for completing the cognitive assessments at age 24
219 years. See Tables S4a and S4b for a detailed description of confounding factors associated
220 with tobacco and cannabis use class membership.

221 *Genetic analyses*

222 *Mendelian randomization (MR)*

223 Two-sample MR was used to test the hypothesised causal effect of smoking initiation
224 and lifetime cannabis use on cognitive functioning. The two-sample MR approach requires
225 summary level data from GWAS, enabling SNP-outcome and SNP-exposure effects to be
226 derived from different data sources. As the genetic instrument for smoking we used 378-
227 independent genome-wide significant SNPs associated with smoking initiation identified by
228 the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN
229 <https://gscan.sph.umich.edu/>) based on a total sample of ~1,200,000 individuals. We used
230 8-independent genome-wide significant SNPs associated with lifetime cannabis use based
231 on the largest GWAS to date ($n=184,765$) (47). As outcomes, we used GWAS conducted in
232 ALSPAC ($n\sim 2,500$) for each of our three primary outcome measures: i) working memory
233 assessed using d' ; ii) response inhibition assessed using SSRT; and iii) emotion recognition
234 assessed using total number of correctly identified emotions (48).

235 Analyses were performed using the TwoSampleMR R package, part of MR-Base
236 (49). The inverse-variance weighted (IVW) approach was used as a primary analysis, with
237 three complementary estimation methods as sensitivity analyses which each make different
238 assumptions about the nature of horizontal pleiotropy (where the genetic variant associates
239 with the outcome via an independent pathway to the exposure): MR Egger (50), weighted

240 median (51), and weighted mode (52). A consistent effect across all of these methods would
241 provide the most confidence that any observed effects are not due to pleiotropy.

242 Next, one-sample MR analyses using two-stage least squares (2SLS) regression
243 models with robust standard errors was used to examine the full GRS for smoking initiation
244 (378 SNPs) as an instrument for smoking initiation and cannabis use (8 SNPs) as an
245 instrument for lifetime cannabis use in relation to the three cognitive assessments at 24
246 years of age. Using individual-level data, the first stage involves regressing tobacco/cannabis
247 use upon individual smoking initiation/lifetime cannabis use SNPs. Lifetime tobacco use
248 (n=1,638/5,107) (32%) up to age 15 years and lifetime cannabis use (n=1,348/5,319) (25%)
249 up to age 24 years were chosen as exposures. Each of the cognitive outcomes were then
250 regressed on the fitted values from the stage 1 for tobacco and cannabis use in the second
251 stage. The three key assumptions in MR are 1) the genetic instrument is robustly associated
252 with the exposure of interest; 2) confounders of the exposure-outcome association are not
253 associated with the genetic instrument; and 3) the genetic instrument is not associated with
254 the outcome other than through its association with the exposure; see (30) for a full
255 description. Power calculations conducted for one-sample MR analyses using mRnd (53)
256 indicated that we had 80% power to detect an effect size of 0.24 for smoking initiation and
257 0.15 for lifetime cannabis use using a sample size of n~3,300 (individuals who had available
258 cognitive data in ALSPAC).

259

260 **RESULTS**

261 *Observational analyses*

262 *Working memory – 2-back task*

263 Unadjusted and adjusted associations between patterns of tobacco/cannabis use
264 from 13 to 18 years and working memory at age 24 are presented in Tables 1a and 1b.
265 There was evidence to suggest that late-onset regular smokers ($b=-0.29$, 95%CI=-0.45 to -
266 0.13) and earl-onset regular smokers ($b=-0.45$, 95%CI=-0.84 to -0.05) showed poorer
267 working memory performance compared to the non-smokers in the fully adjusted model.
268 There was also evidence indicating that early-onset regular cannabis users showed poorer
269 working memory performance compared to the non-cannabis users in the fully adjusted
270 model ($b=-0.62$, 95%CI=-0.93 to -0.31). In the sensitivity analyses, there was some evidence
271 to suggest that early-onset regular tobacco smoking was associated with fewer correct hits
272 on the N-back task in the fully adjusted models (Table S5a).

273 [Tables 1a and 1b]

274 *Response inhibition - stop signal task*

275 Unadjusted and adjusted associations between patterns of tobacco/cannabis use
276 from 13 to 18 years and response inhibition at age 24 are presented in Tables 2a and 2b.
277 The fully adjusted models suggest slower SSRT (indicative of impaired response inhibition) in
278 early-onset regular smokers ($b=0.18$, 95%CI=0.07 to 0.28), and early-onset regular cannabis
279 users ($b=0.30$, 95%CI=0.08 to 0.52) compared to tobacco and cannabis non-users. All
280 associations were supported by significant Wald test values indicating a significant
281 difference between the groups in terms of their ability to inhibit responses. In the sensitivity
282 analyses, there was evidence to suggest that late-onset regular tobacco and early-onset
283 cannabis users were associated with worse Go and Stop accuracy in the fully adjusted
284 models (Tables S6a and S6b).

285 [Tables 2a and 2b]

286 *Emotion recognition – 6AFC task*

287 Unadjusted and adjusted associations between patterns of tobacco/cannabis use
288 from 13 to 18 years and emotion recognition at age 24 are presented in Tables 3a and 3b.
289 There was evidence to suggest that late-onset regular smokers ($b=-0.02$, 95%CI=-0.03 to -
290 0.00), and early-onset regular ($b=-0.04$, 95%CI=-0.08 to -0.01) showed poorer emotion
291 recognition compared to non-smokers in the fully adjusted models. There was insufficient
292 evidence of an association between other patterns of tobacco/cannabis use and emotion
293 recognition. There was some evidence in the sensitivity models to suggest late-onset regular
294 tobacco users had poorer ability to identify ‘fear’ and ‘surprise’, while early-onset regular
295 tobacco users had poorer ability to identify ‘sad’ in the fully adjusted models (Table S7d).
296 Early- and late-onset occasional cannabis users had better ability to identify ‘anger’ and
297 ‘disgust’, while late-onset occasional cannabis users had poorer ability to identify ‘happy’ in
298 the fully adjusted models (Table 8d).

299 [Tables 3a and 3b]

300 *Genetic analyses*

301 Information testing whether the genetic instruments are associated with the confounders
302 are presented in the Supplementary Material (Tables S9a and S9b).

303 *Two-sample Mendelian randomization*

304 Two-sample MR methods provided little evidence to suggest that SNPs associated
305 with smoking initiation were a causal risk factor for deficits in cognitive functioning (Table
306 S4a). Focusing on the IVW estimate as the primary measure, SNPs associated with smoking
307 initiation were not associated with working memory ($b=-0.02$ 95%CI=-0.20 to 0.15; $p=0.52$);
308 response inhibition ($b=-0.06$ 95%CI=-0.24 to 0.12; $p=0.31$); or emotion recognition ($b=0.00$
309 95%CI=-0.18 to 0.18; $p=0.97$). Other sensitivity estimates tended to be in the same direction

310 and failed to demonstrate smoking initiation as a causal risk factor for deficits in cognitive
311 functioning.

312 Similarly, there was little evidence to suggest that SNPs associated with lifetime
313 cannabis use was a causal risk factor for deficits in cognitive functioning (Table S4b).
314 Focusing on the IVW estimate as the primary measure, SNPs associated with lifetime
315 cannabis use were not associated with working memory ($b=0.28$ 95%CI=-0.16 to 0.70;
316 $p=0.21$); response inhibition ($b=-0.13$ 95%CI=-0.47 to 0.22; $p=0.47$); or emotion recognition
317 ($b=-0.08$ 95%CI=-0.52 to 0.36; $p=0.71$). All other sensitivity estimates were in the same
318 direction and failed to demonstrate cannabis use as a causal risk factor for deficits in
319 cognitive functioning.

320 [Tables 4a and 4b]

321 *One-sample Mendelian randomization*

322 Results from the one-sample MR provided little evidence to suggest that smoking
323 initiation or lifetime cannabis use were causal risk factors for deficits in cognitive functioning
324 (Table 5). SNPs associated with smoking initiation were not associated with working
325 memory ($b=0.01$ 95%CI=-0.06 to 0.29; $p=0.21$); response inhibition ($b=0.16$ 95%CI=-0.03 to
326 0.35; $p=0.10$); or emotion recognition ($b=0.00$ 95%CI=-0.18 to 0.18; $p=0.97$). Similarly, SNPs
327 associated with lifetime cannabis use were not associated with working memory ($b=-0.37$
328 95%CI=-0.72 to -0.02; $p=0.04$); response inhibition ($b=0.04$ 95%CI=-0.32 to 0.39; $p=0.85$); or
329 emotion recognition ($b=-0.08$ 95%CI=-0.52 to 0.36; $p=0.71$).

330 [Table 5]

331

332 **DISCUSSION**

333 This observational study provided evidence to suggest an association between
334 tobacco and cannabis use across adolescence and cognitive functioning at age 24. Late-
335 onset regular smokers and early-onset regular cannabis users had poorer working memory
336 performance, slower ability to inhibit responses, and poorer ability to recognise emotions
337 compared to the non-smokers and non-cannabis users. Our results remained largely
338 consistent when controlling for prior measures of substance use and cognition allowing for
339 clear temporality between exposure and outcomes. Genetic analyses were imprecise and
340 did not provide clear evidence to suggest that smoking initiation and lifetime cannabis use
341 were causally related to cognitive functioning in the ALSPAC sample. It is likely that these
342 analyses were underpowered.

343 *Comparison with previous studies*

344 To our knowledge, this is the first study to assess the relationship between tobacco
345 and cannabis use, and subsequent cognitive functioning using a combination of
346 observational and genetic epidemiological approaches. Overall, we found an adverse
347 associations between tobacco/cannabis use and working memory, response inhibition, and
348 emotion recognition in ALSPAC, in that those who initiated use at earlier and later ages, and
349 in those with more frequent use. These findings contribute to a literature of mixed findings
350 regarding the direction of association between tobacco and cannabis exposure and
351 subsequent cognition by suggesting that adolescent tobacco and cannabis use precede
352 observed reductions in cognitive function. These findings support studies that have
353 demonstrated effects may depend on the frequency, duration, and age at onset of use
354 (20,21,54–59).

355 Our study extends previous findings in a number of ways. First, the observational
356 study was better powered than most of the previous studies as it used data from over 3,200

357 participants providing information spanning birth to 24 years of age. Second, identifying
358 heterogeneous patterns of tobacco and cannabis use across this crucial period allows
359 individuals who follow markedly different developmental trajectories to be captured
360 (27,28). Third, the cognitive measures were assessed at a time when they are expected to
361 have reached maturity (2–5), in comparison to previous studies which have examined
362 cognitive functioning at earlier ages while they are still maturing. Examining mature levels of
363 cognitive functioning reduces the possibility that cognitive functioning is influencing earlier
364 tobacco and cannabis use, effects that cannot be disentangled in purely cross-sectional
365 studies. Further, our ability to control for earlier measures of cognitive functioning and
366 substance use, prior to the baseline measures of tobacco and cannabis use helps to rule out
367 the possibility of reverse causation. Fourth, our study sought to examine specificity in
368 cognitive functioning, by using well-validated tests to probe different domains of cognitive
369 functioning instead of focusing on general intelligence. Finally, we sought to triangulate our
370 results by using one- and two-sample MR approaches to assess tobacco and cannabis use as
371 causal risk factors for cognitive functioning. This approach can help to overcome the main
372 sources of bias from classical observational approaches, by providing a more reliable
373 estimate of the likely underlying causal relationship.

374 *Limitations*

375 There are limitations to this study that should be considered. First, the ALSPAC
376 cohort suffers from attrition, which is higher among the socially disadvantaged (60). We
377 attempted to minimize the effect of drop-out by using multiple imputation, FIML, and
378 inverse probability weighting which assume MAR missing patterns. Although it is not
379 possible to test the MAR assumption, it was made more plausible as a number of SES
380 variables were found to predict whether participants attended the clinic or not (Table S1).

381 Second, tobacco and cannabis use were self-reported. However, there is evidence to
382 suggest that self-reported assessments are reliable and valid methods (61), and the
383 assessment of tobacco and cannabis use yearly over 6 years in a latent variable framework
384 helps to account for measurement error (62). Third, it is likely that both the one- and two-
385 sample MR analyses are underpowered. However, findings using weak instruments tend to
386 bias findings towards the null in the two-sample setting and toward the outcome-risk
387 association in the one-sample setting (63). Finally, it is possible that the direction of the
388 association could work in both ways, that is, impairments in cognitive functioning may
389 precede (and increase the risk of developing) tobacco and cannabis use (21,64–66). We
390 were able to include a number of measures to maximize the robustness of our findings: (i)
391 ascertaining the temporal order of exposures and outcomes; (ii) controlling for premorbid
392 working memory and brain insults prior to measures of tobacco/cannabis use helped to
393 reduce the possibility of cognitive impairments, or lower cognitive abilities in childhood,
394 influencing tobacco/cannabis use; and (iii) it is possible that a common risk factor is
395 influencing both tobacco/cannabis use and lower cognitive function, however MR methods
396 helps to protect against this possibility by minimizing bias from reverse causation and
397 residual confounding.

398 *Implications and conclusions*

399 Using a triangulation approach of three separate methods, each with different
400 limitations and potential sources of bias, our study contributes to the understanding of the
401 relationship between adolescent tobacco and cannabis use, and subsequent cognitive
402 functioning. Overall, there was observational evidence that adolescent tobacco and
403 cannabis use were associated with subsequent cognitive functioning, highlighting
404 impairments in a range of cognitive domains, including working memory, response

405 inhibition and emotion recognition. Our findings lend support to the developmental
406 vulnerability hypothesis, in that, tobacco and cannabis use in adolescence, when the brain is
407 undergoing critical development, may have neurotoxic effects. Better powered genetically
408 informed studies are required to determine whether these associations are causal.

409

410 **Acknowledgements:** We are extremely grateful to all the families who took part in this
411 study, the midwives for their help in recruiting them, and the whole ALSPAC team, which
412 includes interviewers, computer and laboratory technicians, clerical workers, research
413 scientists, volunteers, managers, receptionists and nurses. The work was undertaken with
414 the support of the MRC and Alcohol Research UK (grant number MR/L022206/1). We
415 acknowledge also support from The Centre for the Development and Evaluation of Complex
416 Interventions for Public Health Improvement (DECIPHER); a UKCRC Public Health Research
417 Centre of Excellence (joint funding (grant number MR/KO232331/1) from the British Heart
418 Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research
419 Council, the Welsh Government and the Wellcome Trust, under the auspices of the UK
420 Clinical Research Collaboration); and the NIHR School of Public Health Research. Support
421 was also provided by the UK Medical Research Council Integrative Epidemiology Unit at the
422 University of Bristol (MM_UU_00011/7). LM, RW, SS, and MRM are members of the UK
423 Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research Centre of
424 Excellence. LM, REW, SS, and MRM are supported by the NIHR Biomedical Research Centre
425 at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol (BRC-
426 1215-20011) and we acknowledge support from NIHR HPRU in Evaluation. The UK Medical
427 Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol
428 provide core support for ALSPAC. This publication is the work of the authors and Liam

429 Mahedy and Marcus Munafò will serve as guarantors for the contents of this paper. The
430 views expressed in this publication are those of the authors and not necessarily those of the
431 NHS, the National Institute for Health Research or the Department of Health and Social
432 Care. GWAS data were generated by Sample Logistics and Genotyping Facilities at Wellcome
433 Sanger Institute and LabCorp (Laboratory Corporation of America) using support from
434 23andMe. A comprehensive list of grants funding is available on the ALSPAC website
435 (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>).

436 **Disclosures:** CS is employed by Cambridge Cognition. MRM is co-director of Jericoe Ltd,
437 which produces software for the assessment and modification of emotion recognition. LM,
438 RW, SS, MF, JH, & MH report no conflicts of interest.

439

440 REFERENCES

- 441 1. De Bellis MD, Clark DB, Beers SR, Soloff PH, Boring AM, Hall J, et al. Hippocampal
442 volume in adolescent-onset alcohol use disorders. *Am J Psychiatry*. 2000;157(5):737–
443 44.
- 444 2. Fry AF, Hale S. Relationships among processing speed, working memory, and fluid
445 intelligence in children. *Biol Psychol*. 2000;54(1–3):1–34.
- 446 3. Kramer AF, de Sather JCMG, Cassavaugh ND. Development of attentional and
447 oculomotor control. *Dev Psychol*. 2005;41(5):760–72.
- 448 4. Davidson MC, Amso D, Anderson LC, Diamond A. Development of cognitive control
449 and executive functions from 4 to 13 years: evidence from manipulations of memory,
450 inhibition, and task switching. *Neuropsychologia*. 2006;44(11):2037–78.
- 451 5. Thomas LA, De Bellis MD, Graham R, LaBar KS. Development of emotional facial
452 recognition in late childhood and adolescence. *Dev Sci*. 2007;10(5):547–58.
- 453 6. Sowell ER, Delis D, Stiles J, Jernigan TL. Improved memory functioning and frontal
454 lobe maturation between childhood and adolescence: a structural MRI study. *J Int
455 Neuropsychol Soc*. 2001;7(3):312–22.
- 456 7. Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-
457 adolescent brain maturation in frontal and striatal regions. *Nat Neurosci*. 1999;2:859.
- 458 8. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M. The endocannabinoid system and
459 the regulation of neural development: potential implications in psychiatric disorders.
460 *Eur Arch Psychiatry Clin Neurosci*. 2009;259(7):371–82.
- 461 9. Newman LA, McGaughy J. Cholinergic deafferentation of prefrontal cortex increases
462 sensitivity to cross-modal distractors during a sustained attention task. *J Neurosci*.
463 2008;28(10):2642–50.

- 464 10. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. *Curr Pharm Des.*
465 2014;20(13):2186–93.
- 466 11. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in
467 adolescence. *Mol Cell Endocrinol.* 2008;286(1-2 Suppl 1):S108-13.
- 468 12. Slotkin TA. Cholinergic systems in brain development and disruption by
469 neurotoxicants: nicotine, environmental tobacco smoke, organophosphates. *Toxicol*
470 *Appl Pharmacol.* 2004;198(2):132–51.
- 471 13. Dwyer JB, Broide RS, Leslie FM. Nicotine and brain development. *Birth Defects Res C*
472 *Embryo Today.* 2008;84(1):30–44.
- 473 14. Gonzalez R, Pacheco-Colón I, Duperrouzel JC, Hawes SW. Does cannabis use cause
474 declines in neuropsychological functioning? A review of longitudinal studies. *J Int*
475 *Neuropsychol Soc.* 2017;23(9–10):893–902.
- 476 15. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary
477 findings of a longitudinal study of effects on IQ in young adults. *CMAJ.*
478 2002;166(7):887–91.
- 479 16. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al. Impact of
480 adolescent marijuana use on intelligence: Results from two longitudinal twin studies.
481 *Proc Natl Acad Sci U S A.* 2016;113(5):E500-8.
- 482 17. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year
483 trajectory in a young adult cohort. *Addiction.* 2011;106(12):2195–203.
- 484 18. Jacobus J, Squeglia LM, Meruelo AD, Castro N, Brumback T, Giedd JN, et al. Cortical
485 thickness in adolescent marijuana and alcohol users: A three-year prospective study
486 from adolescence to young adulthood. *Dev Cogn Neurosci.* 2015;16:101–9.
- 487 19. Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran H V. Are IQ and

- 488 educational outcomes in teenagers related to their cannabis use? A prospective
489 cohort study. *J Psychopharmacol*. 2016;30(2):159–68.
- 490 20. Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, et al. Associations
491 between adolescent cannabis use and neuropsychological decline: a longitudinal co-
492 twin control study. *Addiction*. 2018;113(2):257–65.
- 493 21. Castellanos-Ryan N, Pingault J-B, Parent S, Vitaro F, Tremblay RE, Seguin JR.
494 Adolescent cannabis use, change in neurocognitive function, and high-school
495 graduation: A longitudinal study from early adolescence to young adulthood. *Dev*
496 *Psychopathol*. 2017;29(4):1253–66.
- 497 22. Morin J-FG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O’Leary-Barrett M, et al. A
498 population-based analysis of the relationship between substance use and adolescent
499 cognitive development. *Am J Psychiatry*. 2018;176(2):98–106.
- 500 23. Slotkin TA. Nicotine and the adolescent brain: insights from an animal model.
501 *Neurotoxicol Teratol*. 2002;24(3):369–84.
- 502 24. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine
503 receptors within midbrain dopamine neurons. *Neuroscience*. 2007;144(4):1347–60.
- 504 25. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of cigarette smoking in
505 young adults--a comparison with pre-drug performance. *Neurotoxicol Teratol*.
506 2006;28(4):517–25.
- 507 26. Weiser M, Zarka S, Werbeloff N, Kravitz E, Lubin G. Cognitive test scores in male
508 adolescent cigarette smokers compared to non-smokers: a population-based study.
509 *Addiction*. 2010;105(2):358–63.
- 510 27. Chen K, Kandel D. The natural history of drug use from adolescence to the mid-
511 thirties in a general population sample. *Am J Public Health*. 1995;85(1):41–7.

- 512 28. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al.
513 Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from
514 the WHO World Mental Health Surveys. *PLoS Med.* 2008;5(7):e141–e141.
- 515 29. Lubke GH, Muthén B. Investigating population heterogeneity with factor mixture
516 models. *Psychol Methods.* 2005;10(1):21–39.
- 517 30. Lawlor D, Richmond R, Warrington N, McMahon G, Davey Smith G, Bowden J, et al.
518 Using Mendelian randomization to determine causal effects of maternal pregnancy
519 (intrauterine) exposures on offspring outcomes: Sources of bias and methods for
520 assessing them. *Wellcome open Res.* 2017;2:11.
- 521 31. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile:
522 the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of
523 Parents and Children. *Int J Epidemiol.* 2013;42(1):111–27.
- 524 32. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al.
525 Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers
526 cohort. *Int J Epidemiol.* 2013;42(1):97–110.
- 527 33. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al. The Avon
528 Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled
529 sample of index children in 2019. *Wellcome Open Res.* 2019;4:51.
- 530 34. Howe LJ, Trela-Larsen L, Taylor M, Heron J, Munafo MR, Taylor AE. Body mass index,
531 body dissatisfaction and adolescent smoking initiation. *Drug Alcohol Depend.* 2017
532 Sep;178:143–9.
- 533 35. Taylor M, Collin SM, Munafo MR, MacLeod J, Hickman M, Heron J. Patterns of
534 cannabis use during adolescence and their association with harmful substance use
535 behaviour: findings from a UK birth cohort. *J Epidemiol Community Health.* 2017

- 536 Aug;71(8):764–70.
- 537 36. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
538 data capture (REDCap)--a metadata-driven methodology and workflow process for
539 providing translational research informatics support. *J Biomed Inform.*
540 2009;42(2):377–81.
- 541 37. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap
542 consortium: Building an international community of software platform partners. *J*
543 *Biomed Inform.* 2019;95(5):103208.
- 544 38. Kirchner WK. Age differences in short-term retention of rapidly changing information.
545 *J Exp Psychol.* 1958;55(4):352–8.
- 546 39. Wardle MC, de Wit H, Penton-Voak I, Lewis G, Munafò MR. Lack of association
547 between COMT and working memory in a population-based cohort of healthy young
548 adults. *Neuropsychopharmacology.* 2013;38(7):1253–63.
- 549 40. Rossi R, Zammit S, Button KS, Munafò MR, Lewis G, David AS. Psychotic experiences
550 and working memory: a population-based study using signal-detection analysis. *PLoS*
551 *One.* 2016;11(4):e0153148–e0153148.
- 552 41. Mahedy L, Field M, Gage S, Hammerton G, Heron J, Hickman M, et al. Alcohol use in
553 adolescence and later working memory: Findings from a large population-based birth
554 cohort. *Alcohol Alcohol.* 2018;53:251–8.
- 555 42. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction
556 time responses: a model and a method. *J Exp Psychol Hum Percept Perform.*
557 1984;10(2):276–91.
- 558 43. Band GPH, van der Molen MW, Logan GD. Horse-race model simulations of the stop-
559 signal procedure. *Acta Psychol (Amst).* 2003;112(2):105–42.

- 560 44. Penton-Voak IS, Bate H, Lewis G, Munafo MR. Effects of emotion perception training
561 on mood in undergraduate students: randomised controlled trial. *Br J Psychiatry*.
562 2012;201(1):71–2.
- 563 45. Bolck A, Croon M, Hagenars J. Estimating latent structure models with categorical
564 variables: one-step versus three-step estimators. *Polit Anal*. 2004;12(1):3–27.
- 565 46. Muthén LK, Muthén BO. *User’s Guide*. 7th ed. Muthén LK, Muthén BO, editors. Los
566 Angeles, CA: Muthén & Muthén; 2016.
- 567 47. Pasma JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS
568 of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits,
569 and a causal influence of schizophrenia. *Nat Neurosci*. 2018;21(9):1161–70.
- 570 48. Mahedy L, Suddell S, Skirrow C, Wootton R, Fernandes GS, Heron J, et al. Alcohol use
571 and cognitive functioning in young adults: an observational and Mendelian
572 randomisation study. *medRxiv*. 2019;19003327.
- 573 49. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
574 platform supports systematic causal inference across the human phenome. *Elife*.
575 2018 May;7.
- 576 50. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
577 instruments: effect estimation and bias detection through Egger regression. *Int J*
578 *Epidemiol*. 2015;44(2):512–25.
- 579 51. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian
580 randomization with some invalid instruments using a weighted median estimator.
581 *Genet Epidemiol*. 2016;40(4):304–14.
- 582 52. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
583 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*.

- 584 2017;46(6):1985–98.
- 585 53. Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian
586 randomization studies. *Int J Epidemiol*. 2012;42(5):1497–501.
- 587 54. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al.
588 Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry*.
589 2011;198(6):442–7.
- 590 55. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WDS. Age of onset of
591 marijuana use impacts inhibitory processing. *Neurosci Lett*. 2012;511(2):89–94.
- 592 56. Mashhoon Y, Betts J, Farmer SL, Lukas SE. Early onset tobacco cigarette smokers
593 exhibit deficits in response inhibition and sustained attention. *Drug Alcohol Depend*.
594 2018;184:48–56.
- 595 57. Goriounova NA, Mansvelder HD. Short- and long-term consequences of nicotine
596 exposure during adolescence for prefrontal cortex neuronal network function. *Cold
597 Spring Harb Perspect Med*. 2012;2(12):a012120–a012120.
- 598 58. Mokrysz C, Freeman TP, Korkki S, Griffiths K, Curran H V. Are adolescents more
599 vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study
600 in human males. *Transl Psychiatry*. 2016;6(11):e961–e961.
- 601 59. Boccio CM, Beaver KM. Examining the influence of adolescent marijuana use on adult
602 intelligence: Further evidence in the causation versus spuriousness debate. *Drug
603 Alcohol Depend*. 2017;177:199–206.
- 604 60. Wolke D, Waylen A, Samara M, Steer C, Goodman R, Ford T, et al. Selective drop-out
605 in longitudinal studies and non-biased prediction of behaviour disorders. *Br J
606 Psychiatry*. 2009;195(3):249–56.
- 607 61. Boykan R, Messina CR, Chateau G, Eliscu A, Tolentino J, Goniewicz ML. Self-reported

- 608 use of tobacco, E-cigarettes, and marijuana versus urinary biomarkers. *Pediatrics*.
609 2019;143(5).
- 610 62. Bray BC, Lanza ST, Tan X. Eliminating bias in classify-analyze approaches for latent
611 class analysis. *Struct Equ Model*. 2015;22(1):1–11.
- 612 63. Davies NM, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: a
613 guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.
- 614 64. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE.
615 Effect of baseline cannabis use and working-memory network function on changes in
616 cannabis use in heavy cannabis users: A prospective fMRI study. *Hum Brain Mapp*.
617 2014;35(5):2470–82.
- 618 65. Squeglia LM, Jacobus J, Nguyen-Louie TT, Tapert SF. Inhibition during early
619 adolescence predicts alcohol and marijuana use by late adolescence.
620 *Neuropsychology*. 2014;28(5):782–90.
- 621 66. Anokhin AP, Golosheykin S. Neural Correlates of Response Inhibition in Adolescents
622 Prospectively Predict Regular Tobacco Smoking. *Dev Neuropsychol*. 2016;41(1–2):22–
623 37.
- 624




Figure 1a. Distribution of tobacco use across latent classes at each timepoint ($n=8,525$). Class proportions based on estimated posterior probability¹.

¹ Tobacco use at age 13 was omitted from the figure as 'daily smoking' was not recorded at this age. Overall, the 'non-users' reported a low probability of tobacco use across all measurement occasions; 'experimenters' were mostly characterised by smoking on the later measurement occasions only; 'late-onset regular' smokers were mostly characterised by smoking on a daily basis in the later measurement occasions only; while 'early-onset regular' smokers were mostly characterised by smoking on a daily basis across timepoints from age 14 years onwards.




Figure 1b. Distribution of cannabis use across latent classes at each timepoint ($n=8,093$). Class proportions based on estimated posterior probability².

² The 'non users' reported a low probability of cannabis use across all measurement occasions; 'late-onset occasional' cannabis users were mostly characterised by cannabis use on the later measurement occasions only; 'early-onset occasional' cannabis users were mostly characterised by occasional cannabis use across all measurements; while 'regular cannabis users' were mostly characterised by cannabis use across timepoints with increasing involvement from age 15 years onwards.

Table 1a. Smoking patterns from 13 to 18 years and working memory at age 24 (higher d' scores reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
$n=3,232$ for all models	Reference group	b (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Working memory d'	-	0.01 (-0.10, 0.10)	-0.32 (-0.48, -0.16)	-0.50 (-0.89, -0.10)	28.92 (3) $p<0.001$
Adjusted for SES					
Working memory d'	-	0.00 (-0.11, 0.11)	-0.28 (-0.44, -0.12)	-0.39 (-0.78, 0.01)	19.78 (3) $p<0.001$
Adjusted for SES/WM/HI					
Working memory d'	-	0.01 (-0.10, 0.11)	-0.27 (-0.43, -0.11)	-0.42 (-0.81, -0.02)	20.25 (3) $p<0.001$
Fully adjusted models					
Working memory d'	-	0.01 (-0.12, 0.10)	-0.29 (-0.45, -0.13)	-0.45 (-0.84, -0.05)	22.12 (3) $p<0.001$

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 1b. Patterns of cannabis use from 13 to 18 years and working memory at age 24 (lower d' reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
$n=3,232$ for all models	Reference group	b (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Working memory d'	-	-0.01 (-0.13, 0.12)	0.24 (-0.05, 0.52)	-0.58 (-0.90, -0.26)	14.10 (3) $p=0.003$
Adjusted for SES					
Working memory d'	-	-0.06 (-0.18, 0.07)	0.17 (-0.11, 0.45)	-0.60 (-0.91, -0.30)	16.26 (3) $p<0.001$
Adjusted for SES/WM/HI					
Working memory d'	-	-0.09 (-0.21, 0.04)	0.15 (-0.12, 0.43)	-0.60 (-0.91, -0.30)	17.64 (3) $p<0.001$
Fully adjusted models					
Working memory d'	-	-0.10 (-0.22, 0.03)	0.12 (-0.17, 0.41)	-0.62 (-0.93, -0.31)	18.56 (3) $p<0.001$

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 2a. Smoking patterns from 13 to 18 years and response inhibition at age 24 (shorter reaction times reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
<i>n</i> =3,232 for all models	Reference group	<i>b</i> (95% CI)	<i>b</i> (95% CI)	<i>b</i> (95% CI)	Wald (df) <i>p</i> value
Unadjusted models					
Stop signal reaction time	-	0.02 (-0.05, 0.09)	0.19 (-0.02, 0.40)	0.21 (0.10, 0.31)	22.73 (3) <i>p</i> <0.001
Adjusted for SES					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.08 (-0.13, 0.30)	0.18 (0.07, 0.28)	13.04 (3) <i>p</i> =0.005
Adjusted for SES/WM/HI					
Stop signal reaction time	-	0.01 (-0.06, 0.08)	0.10 (-0.12, 0.32)	0.17 (0.07, 0.27)	13.05 (3) <i>p</i> =0.005
Fully adjusted model					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.10 (-0.12, 0.32)	0.18 (0.07, 0.28)	12.78 (3) <i>p</i> =0.005

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; positive estimates indicate poorer performance

Table 2b. Patterns of cannabis use from 13 to 18 years and response inhibition at age 24 (longer reaction times reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
<i>n</i> =3,232 for all models	Reference group	<i>b</i> (95% CI)	<i>b</i> (95% CI)	<i>b</i> (95% CI)	Wald (df) <i>p</i> value
Unadjusted models					
Stop signal reaction time	-	0.00 (-0.07, 0.08)	0.03 (-0.13, 0.18)	0.29 (0.06, 0.52)	7.02 (3) <i>p</i> =0.07
Adjusted for SES					
Stop signal reaction time	-	0.02 (-0.06, 0.10)	0.04 (-0.13, 0.20)	0.30 (0.07, 0.52)	8.03 (3) <i>p</i> =0.04
Adjusted for SES/WM/HI					
Stop signal reaction time	-	0.04 (-0.04, 0.11)	0.04 (-0.12, 0.21)	0.30 (0.08, 0.52)	9.25 (3) <i>p</i> =0.02
Fully adjusted model					
Stop signal reaction time	-	0.04 (-0.04, 0.11)	0.05 (-0.11, 0.22)	0.30 (0.08, 0.52)	9.24 (3) <i>p</i> =0.02

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 3a. Smoking patterns from 13 to 18 and emotion recognition at age 24 (lower scores reflect poorer performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
<i>n</i> =3,232 for all models	Reference group	<i>b</i> (95% CI)	<i>b</i> (95% CI)	<i>b</i> (95% CI)	Wald (df) <i>p</i> value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.01)	-0.02 (-0.04, -0.01)	-0.05 (-0.08, -0.01)	20.32 (3) <i>p</i> <0.001
Adjusted for SES					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.07, -0.01)	14.45 (3) <i>p</i> =0.002
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	14.65 (3) <i>p</i> =0.002
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	16.43 (3) <i>p</i> =0.001

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table 3b. Patterns of cannabis use from 13 to 18 and emotion recognition at age 24 (higher scores reflect better performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
<i>n</i> =3,232 for all models	Reference group	<i>b</i> (95% CI)	<i>b</i> (95% CI)	<i>b</i> (95% CI)	Wald (df) <i>p</i> value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.02)	0.03 (0.00, 0.06)	-0.03 (-0.06, 0.00)	7.71 (3) <i>p</i> =0.05
Adjusted for SES					
Total hits	-	0.00 (-0.01, 0.01)	0.03 (0.00, 0.05)	-0.02 (-0.05, 0.01)	4.68 (3) <i>p</i> =0.20
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	0.03 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.50 (3) <i>p</i> =0.21
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	0.02 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.23 (3) <i>p</i> =0.24

Note. SES: socioeconomic status; WM: working memory at age ~11 years; HI: head injury/ unconsciousness up to age 11 years; Wald tests determine whether there were differences between patterns of tobacco use and subsequent cognitive functioning; negative estimates indicate poorer performance

Table S4a. Two-sample MR analyses of the effects of smoking initiation on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Smoking initiation	Working memory	Inverse-Variance Weighted	341	0.01 (-0.06, 0.29)	0.21
		MR Egger (SIMEX)	341	-0.68 (-1.41, 0.06)	0.07
		Weighted Median	341	0.06 (-0.21, 0.32)	0.65
		Weighted Mode	341	-0.32 (-1.11, 0.48)	0.43
Smoking initiation	Response inhibition	Inverse-Variance Weighted	341	0.16 (-0.03, 0.35)	0.10
		MR Egger (SIMEX)	341	1.30 (-2.22, 0.03)	0.02
		Weighted Median	341	0.21 (-0.07, 0.49)	0.14
		Weighted Mode	341	0.30 (-0.55, 1.16)	0.49
Smoking initiation	Emotion recognition	Inverse-Variance Weighted	341	0.00 (-0.18, 0.18)	0.97
		MR Egger (SIMEX)	341	0.04 (-0.71, 0.79)	0.91
		Weighted Median	341	-0.05 (-0.31, 0.21)	0.68
		Weighted Mode	341	-0.19 (-1.04, 0.67)	0.67

Table S4b. Two-sample MR analyses of the effects of lifetime cannabis use on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Lifetime cannabis use	Working memory	Inverse-Variance Weighted	8	-0.37 (-0.72, -0.02)	0.04
		MR Egger (SIMEX)	8	-0.10 (-0.21, 0.03)	0.17
		Weighted Median	8	-0.38 (-0.81, 0.06)	0.09
		Weighted Mode	8	-0.21 (-0.85, 0.43)	0.55
Lifetime cannabis use	Response inhibition	Inverse-Variance Weighted	8	0.04 (-0.32, 0.39)	0.85
		MR Egger (SIMEX)	8	0.50 (-0.22, 0.02)	0.32
		Weighted Median	8	0.22 (-0.24, 0.68)	0.35
		Weighted Mode	8	0.26 (-0.35, 0.87)	0.43
Lifetime cannabis use	Emotion recognition	Inverse-Variance Weighted	8	-0.08 (-0.52, 0.36)	0.71
		MR Egger (SIMEX)	8	0.06 (-0.22, 0.03)	0.93
		Weighted Median	8	0.02 (-0.46, 0.48)	0.95
		Weighted Mode	8	0.01 (-0.67, 0.69)	0.98

Table 5. One-sample MR analyses of the effects of smoking initiation on cognitive functioning (standardised coefficients)

	β	se	95% CI	p	F statistic
Smoking initiation					
Working memory	-0.38	0.58	-1.51, 0.75	0.51	14.63
Response inhibition	-0.27	0.53	-1.31, 0.77	0.61	18.12
Emotion recognition	-0.53	0.54	-1.59, 0.53	0.33	17.57
Lifetime cannabis use					
Working memory	-1.41	0.97	-3.31, 0.49	0.14	6.70
Response inhibition	0.02	0.68	-1.31, 1.35	0.98	8.87
Emotion recognition	-0.04	0.69	-1.35, 1.27	0.95	8.79